98%
921
2 minutes
20
Due to the sudden emergence and burnout nature of Marburg virus (MARV) outbreaks, little is known about MARV's pathogenicity and immunogenicity. These gaps in knowledge are limiting our understanding of the disease and the implementation of cost-effective prevention and control measures including case management through safe and effective therapeutic modalities. Therefore, this review aims to synthesize and summarize evidence about pathogenicity, immunogenicity, and virulence in humans towards MARV. Upon infection, MARV rapidly disseminates throughout various tissues, provoking severe cellular injury, particularly in lymphatic organs, the liver, kidneys, and the gastrointestinal tract. The virus takes advantage of host cells by avoiding immune responses, mainly by disrupting the function of dendritic cells and blocking the signaling pathways for interferon. As a result, patients experience profound immune dysregulation characterized by early lymphocyte depletion and a shift towards pro-inflammatory cytokine release, resulting in a cytokine storm that can lead to hemorrhagic septic shock. Additionally, adaptive immune responses, including antibody production, are impaired, further complicating recovery and increasing susceptibility to severe disease outcomes. Understanding these intricate host-pathogen interactions is critical for developing effective therapeutic strategies and vaccines against MARV. Continuing research is essential to explain the mechanisms of immune evasion and to identify potential intervention points for improving patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12030746 | PMC |
http://dx.doi.org/10.3390/pathogens14040323 | DOI Listing |
Biochem Biophys Res Commun
September 2025
Department of Botany, Bioinformatics and Climate Change Impacts Management, School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India. Electronic address:
A primary concern for world health is the emergence of new infectious diseases. Conventional vaccine development techniques are time-consuming and often limited by issues such as antigen availability and safety concerns. Immunoinformatics, a computational approach that integrates immunology and informatics, presents a promising solution for accelerating vaccine design.
View Article and Find Full Text PDFEBioMedicine
September 2025
Albert B. Sabin Vaccine Institute, 2000 Pennsylvania Ave, NW, Suite 7000, Washington, DC, 20006, USA. Electronic address:
Background: Sudan virus and Marburg virus are high priority biological threat pathogens with fatality rates of 25-90%. Recent outbreaks in Uganda, Equatorial Guinea, and Rwanda between 2022 and 2025 emphasise the critical need for effective vaccines. The aim of this phase 1b study was to determine clinical safety, tolerability, and immunogenicity of these monovalent vaccines.
View Article and Find Full Text PDFVaccine
September 2025
Department of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, HI 96813, USA. Electronic address:
Filoviruses, including the well-known Ebola virus, are among the most lethal pathogens known. The current vaccine landscape is constrained by stringent cold chain requirements making vaccine deployment challenging, especially in regions with limited infrastructure. ERVEBO®, the sole FDA-approved filovirus vaccine, requires ultra-cold storage.
View Article and Find Full Text PDFMicrob Biotechnol
September 2025
KU Leuven, Department of Biosystems, Laboratory of Gene Technology, Leuven, Belgium.
In this millennium, Marburgvirus (MARV) outbreaks with very high mortality but still small case numbers (< 400) were observed with increasing frequency in Africa. Ecologists identified Egyptian Rousettus bats (ERB) as viral reservoir species causing occasional zoonotic spillover events, mostly in humans intruding into their cave habitats as miners or tourists. So far only short human-to-human transmission chains have been documented.
View Article and Find Full Text PDFNat Commun
September 2025
Department of Biosciences and Medical Biology, University of Salzburg, Salzburg, Austria.
Proprotein convertases (PCs), including furin and PC1/3 among nine mammalian homologues, mediate the maturation of numerous secreted substrates by proteolytic cleavage. Disbalance of PC activity is associated with diseases like cancer, fibrosis, neurodegeneration and infections. Therefore, PCs are promising drug targets for the treatment of many diseases.
View Article and Find Full Text PDF